Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 22;105(6):1527–1538. doi: 10.3324/haematol.2019.217414

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 3. — Variable dose-dependent activity of venetoclax on leukocytes. (A) Scatter diagram displaying dose-dependent cytotoxicity of venetoclax (1-10,000 nM) in CD45⁺ (upper panel) and CD45⁺CD19⁺ (lower panel) cells for a single patient. (B) Averaged dose response graphs generated for different immune cell subtypes derived from healthy (n=3), acute myeloid leukemia (AML) (n=3), and multiple myeloma (MM) (n=10) samples showed venetoclax sensitivity in CD19⁺/B cells with an IC₅₀ <1 nM. CD3⁺CD4⁻cytotoxic T cells were more sensitive compared to CD3⁺CD4⁺ T-helper cells. Data are presented as mean±standard error of mean responses for the tested samples in each disease group. Mean IC₅₀ values for the analyzed samples are listed in Online Supplementary Table S4.